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Abstract
The chapter introduces the steps to achieving proper wound care in immunobullous 
disease. It describes the clinical characteristics and nature of “wounds” formed in pem-
phigus versus pemphigoid diseases. Namely, pemphigus diseases typically result in 
acantholysis in the epidermis and the formation of flaccid blisters. In contrast, bullous 
pemphigoid presents with basal keratinocyte hemidesmosomes in the dermoepidermal 
junction, which results in a split at the dermoepidermal junction and clinically forms 
tense blisters. Therefore, there is a separate protocol for treating the wounds in each of 
these diseases, which must take additional patient specific factors into consideration.
Keywords: wound, care, wound healing, wound dressing, immunobullous disease, 
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1. Introduction
Patients suffering from immunobullous disease have open wounds with a tendency to 
develop new blisters, which presents a unique problem when addressing wound care. These 
patients also have fragile skin limiting the use of adhesives. Immunosuppressant treatments 
increase infection risk and also prednisone slows wound healing but is needed to treat the 
disease. Therefore, there are many complexities surrounding proper wound care specific to 
these patients.
Clinical experience has shaped the steps to achieving wound care in immunobullous disease, 
but more research must be conducted to determine the best wound dressings for this critical 
patient population. While there are many similarities in the wound care of the pemphigus 
versus pemphigoid family, the differences in the nature of wounds formed in each of these 
diseases, calls for a unique plan.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the t rms of the Crea ive
Comm ns Attribution Lic nse (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Introduction to pemphigus
Pemphigus is a group of autoimmune blistering diseases of both the skin and mucosa, which 
is caused by the loss of cell to cell adhesion of keratinocytes which leads to intraepidermal 
blisters [1].
The classic forms are pemphigus vulgaris and pemphigus foliaceus. Pemphigus vulgaris most 
frequently presents with mucous membrane erosions (see Figure 1). Additionally, more than 
half of the patient population will also have cutaneous blisters and erosions. These blisters 
form in the deeper portion of the epidermis, directly above the basal cell layer. Pemphigus 
vegetans is a variant of pemphigus vulgaris that occurs as a result of polymicrobial superin-
fection of lesions [2].
In contrast, patients with pemphigus foliaceus only have cutaneous involvement, and lack 
mucosal lesions. The splits occur in the superficial part of the epidermis, mostly in the granu-
lar layer. Pemphigus erythematosus and fogo selvagem are localized and endemic variants of 
pemphigus foliaceus [3].
Paraneoplastic pemphigus was recently recognized as a disease distinct from the classic forms 
of pemphigus. These patients have a known or occult neoplasm, commonly of lymphoid tis-
sue. Paraneoplastic pemphigus also features painful, severe oral and often conjunctival ero-
sions [1].
Aside from the three classical cases are other less prevalent versions. IgA pemphigus is 
characterized by IgA (as opposed to IgG) autoantibodies directed against keratinocyte cell 
surfaces and can either be the intraepidermal neutrophilic type (IEN) which forms pustules 
throughout the entire epidermis, or the subcorneal pustular dermatosis (SPD) type, with pus-
tules primarily in the upper epidermis [1].
Figure 1. Patient with oral lesions in pemphigus vulgaris.
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3. Pathogenesis of pemphigus
All forms of pemphigus are a result of acantholysis, or the separation of keratinocytes from 
one another. The first step in this disease process is the dissolution of the intercellular sub-
stance, which leads to the separation of desmosomes. This results in the formation of a cleft 
within the epidermis, which expands to become bulla [1].
In every form of pemphigus, there are intercellular autoantibodies against keratinocyte cell-
surface antigens, which are circulating and skin fixed. 80% of patients with active disease 
have circulating intercellular antibodies, and their titer usually correlates with disease activ-
ity. 90% of patients have tissue-fixed intercellular antibodies present in lesions and adjacent 
healthy skin. While the most prevalent antibodies are IgG, there are also frequently deposits 
of IgM, IgA and the complement protein C3. Since intercellular antibodies are uncommon 
when patients do not have pemphigus, they are very useful in making a diagnosis [1].
There is evidence that these intercellular antibodies are pathogenic. First of all, they are able 
to induce the histological changes of pemphigus (acantholysis) in organ cultures of human 
skin, and induce clinical and histologic lesions of pemphigus when passively administered to 
neonatal mice. Further studies reveal that placental transfer of maternal autoantibodies can 
induce transient lesions of the disease in newborn babies of women with active pemphigus 
vulgaris. Specifically absorbing out antibodies against desmoglein 1 or desmoglein 3 has been 
shown to prevent the passive transfer of disease in mice with pemphigus [4].
In pemphigus, the intercellular antibodies are directed against many keratinocyte cell-surface 
antigens, including desmoglein 1 and desmoglein 3. Both of these molecules are desmosomal 
transmembrane proteins in the cadherin family. The pathogenic antibodies against these pro-
teins attack the portion of the protein that is expressed on the external surface of the cells and 
multiple epitopes on the same molecule can be targeted. In pemphigus vulgaris, intercellular 
antibodies are predominantly directed against desmoglein 3 and less often against desmo-
glein 1. However, in pemphigus foliaceus, the antibodies are mostly directed against desmo-
glein 1. Serological analysis has proposed that antibodies are also directed to other antigens, 
which was confirmed when pemphigus like lesions were induced in mice given intercellular 
antibodies not directed against desmoglein 1 or 3 [5]. It was observed that these additional 
antigens included acetylcholine receptors on keratinocytes.
Additionally, the subclass of the antibody response seems to dictate whether intercellu-
lar antibodies cause clinical disease. While IgG1 antibodies against desmoglein 3 are pres-
ent in equal frequency in individuals with or without pemphigus vulgaris, IgG4 antibodies 
are almost exclusively present in patients with active disease [4]. Similarly, IgG1 antibodies 
against desmoglein are present in both individuals with or without endemic pemphigus and 
with or without active. It is believed that in endemic pemphigus, an unknown environmental 
agent might trigger the production of non-pathogenic IgG1 antibodies against desmoglein 1. 
However, the appearance of a clinical disease might be triggered by the presence of an HLA 
susceptibility gene required for the production of a pathogenic IgG4 response [4].
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The exact process by which intercellular antibodies cause loss of cellular adhesion is not yet eluci-
dated, though it does seem that the subclass of IgG response plays a role. There are various theo-
ries surrounding the exact mechanism. It is possible that the antibodies either physically block 
adhesion sites on desmoglein or on other adhesion molecules, or maybe they interfere with their 
structure or other functions or with the assembly of desmosomes. It is also possible that the anti-
bodies stimulate release of proteolytic enzymes. In staphylococcal scalded skin syndrome, which 
is caused by a toxin that binds to and cleaves desmoglein 1, patients form blisters similar to those 
caused by pemphigus foliaceus [6]. Finally, one last possibility of the mechanism is that the anti-
bodies trigger a signaling event which leads to reorganization of the cytoskeleton of keratinocytes, 
and causes the affected cells to shrink, pull away, and separate from adjacent keratinocytes [6].
4. Introduction to pemphigoid
The pemphigoid group can be broken down into bullous pemphigoid, mucous membrane 
(cicatricial) pemphigoid, as well as epidermolysis bullosa acquisita.
Bullous pemphigoid is the most prevalent subepidermal blistering disease of the skin. It is 
most common in the elderly and is correlated with significant morbidity. The typical presen-
tation is a generalized bullous eruption (Figure 2), but it frequently varies in the early stages 
of the disease. In this disease, patients typically make autoantibodies against two components 
of hemidesmosomes, which are the junctional adhesion complexes found in skin.
Mucous membrane pemphigoid is a very rare autoimmune subepithelial blistering disorder 
that has several notable features. It typically involves the mucosae, follows a sustained course, 
and tends to scar the affected areas. This disorder is a “disease phenotype” that encompasses a 
heterogeneous group of blistering disease, which tend to affect mucosal surfaces. Most patients 
Figure 2. Patient with bullous pemphigoid with intact bulla on lower leg.
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have linear deposits of immunoglobulins and/or complement components along the epithelial 
basement membrane zone of the skin and mucosae. There are classically low levels of circulat-
ing anti-basement membrane autoantibodies detected in the serum of some patients, at a low 
titer. This disease is recurrent and progressive and can have serious complications. If atrophic 
scarring and fibrosis affect the conjunctivae, it can ultimately lead to blindness [7].
Epidermolysis bullosa acquisita (EBA) is also a very rare disease. It is an acquired subepider-
mal bullous disease in which the patient has autoimmunity to type VIII collagen, which is the 
major component of the anchoring fibrils of the dermal-epidermal junction. Patients vary in 
the clinical presentation of this disease; some patients have a mechanobullous disorder that 
resembles dystrophic epidermolysis bullosa, while others have symptoms similar to bullous 
pemphigoid or mucous membrane pemphigoid [8] (Figure 3).
5. Pathogenesis of pemphigoid family
Bullous pemphigoid is immune-mediated and linked to a humoral and cellular response 
directed against two isolated self-antigens: BP antigen 180 (BP180, BPAG2 or type XVII colla-
gen) and BP antigen 230 (BP230 or BPAG1e). BP antigen 180 is a transmembrane protein with 
a large collagenous extracellular domain. BP 230 is a cytoplasmic protein that is a member of 
the plakin family. Both of these antigens are components of hemidesmosomes, which are criti-
cal for epithelial-stromal adhesion in stratified and other complex epithelia [1].
Mucous membrane pemphigoid presents with mucocutaneous lesions, which are believed to 
be a result of when autoantibodies bind to the basement membrane zone of stratified epithelia 
of mucosa and skin. These autoantibodies bind to extracellular antigenic sites located within the 
anchoring filament zone, rather than within the hemidesmosomal plaque. However, the exact 
Figure 3. Patient with epidermolysis bullosa acquisita with mucosal lesion.
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pathogenicity of autoantibodies involved in this disease has not been fully elucidated. In some 
patients with mucous membrane pemphigoid, NC16A domain-specific T cells were identified. 
Additionally, it was found that when patients have ocular disease, there is increased expression 
of collagen-binding heat shock protein 47 (HSP47) and TGF-B1 by conjunctival fibroblasts that 
might be associated with conjunctival scarring [7]. There are four subgroups of mucous mem-
brane pemphigoid patients, based on the reactivity profile of patients’ autoantibodies (Table 1).
Epidermolysis bullosa acquisita is also an immune-mediated disease. These patients have tis-
sue-bound and circulating autoantibodies to a structural component of the dermal-epidermal 
junction. There is tissue injury where these antibody–antigen complexes are found. The role 
of these autoantibodies in causing disease has been reaffirmed by in vitro and in vivo animal 
models of the disease [8].
6. Wounds
6.1. Wounds in pemphigus vulgaris
Pemphigus vulgaris typically presents with painful, non-healing ulcerations in the mouth. 
These blisters rupture soon after forming and leave an ulcerated area. There are usually many 
ulcerations that are superficial and irregular in shape, which arise from mucosa of healthy 
appearance. The lesions most commonly form on the buccal and labial mucosa, the palate and 
the tongue. However, it is possible for any mucosal surface to be involved. In contrast to the 
oral lesions of aphthous stomatitis or viral infections that heal in a matter of days or weeks, 
these ulcerations usually will not heal on their own [9].
Due to the rarity of the disease, there is on average a 10-month delay in diagnosis and pem-
phigus only considered when lesions have remained for weeks to months, in spite of anti-
biotic, antifungal or antiviral therapy [10]. If there are multiple, non-healing oral ulcers that 
persist for longer than a month, pemphigus should be considered.
As the disease progresses over the following weeks to months, lesions begin to appear on the 
skin and with symptoms signifying nasal and esophageal involvement. Sometimes, the disease 
begins to manifest with skin lesions. The skin lesions begin as small blisters that are filled with 
Autoantigens Location
BPAg2 (BP180) Hemidesmosome/Lamina lucida (transmembrane)
BPAg1 (BP230) Hemidesmosome (intracellular)
Integrin subunits α6/β4 Hemidesmosome (transmembrane)
Laminin-5 (laminin-332/epiligrin, α-3, β-3, γ-2 chains) Lower lamina lucida
Laminin-6 Lower lamina lucida
Type VII collagen Lamina densa/Sub-lamina densa
Table 1. Autoantigen in bullous pemphigoid, mucous membrane pemphigoid & epidermolysis bullosa acquisita and 
their localization within the dermis/epidermis junction (DEJ).
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a clear fluid that arises from seemingly normal skin. The blisters are usually flaccid, since the 
overlying epidermis is thin and cannot sustain much pressure. Since the blisters are so fragile, 
they usually rupture in several days and form coin sized erosions often with a collarette of epi-
dermis. The lesions are most frequently found on the scalp, upper chest and back. They are more 
commonly found on the medial or central part of the torso rather than the sides. The face and 
neck are also commonly involved, but lesions can appear on any surface covered by stratified 
squamous epithelium. It is important to also check the per inguinal areas, the pharynx and lar-
ynx, manifested by nasal congestion and morning mucous discharge. A recent systematic study 
showed that 49% of patients had symptoms of laryngeal or nasal involvement, or both [11].
If the lesions are left untreated, the bullae and erosions spread. As with burns, widespread 
lesions can be complicated by severe infection or metabolic disturbance, or both, leading to 
death. Prior to the development of systemic corticosteroids, about 75% of patients who devel-
ops pemphigus vulgaris died within a year [11]. However, improved diagnostic techniques 
now permit the recognition of subtler forms of disease. The severity of pemphigus can vary 
widely. There are milder forms that regress spontaneously and the progression of even the 
most severe forms can almost always be reversed with appropriate treatment.
Following treatment, lesions heal with crusting followed by reepithelization. While there is 
no scarring, there can be residual hyperpigmentation at sites of former lesions. The hyper-
pigmentation will usually disappear over several months. At some point, these patients can 
enter a phase of partial or complete remission. In partial remission, they can be maintained, 
lesion-free with minimum (<15 mg per day prednisone) doses of corticosteroids. In complete 
remission, they are lesion free for 2 months and do not need any therapy [9].
A longitudinal study was performed, which assessed the outcome of 40 patients. It showed 
that half of the patients reached complete and long-lasting remission after 5 years and three 
quarters reached the same end point after 10 years [9].
Despite the complete or partial remission, it is fairly typical for flares of disease activity to occur. 
The flare can present with new lesions and itching. There are many factors that are thought to 
possibly trigger a flare, including arthropod bites, hospitalization, dental work, exposure to 
the sun, cutaneous trauma, infection, as well as other forms of physical or emotional stress [9].
The wounds in pemphigus vegetans are very similar to pemphigus vulgaris, however, heal-
ing is accompanied by vegetating proliferation of the epidermis. The lesions present in inter-
triginous areas of the skin, including the axilla of the arm, the groin and the inframammary 
area and scalp. Due to the nature of the location of these lesions, they are often secondarily 
infected, which further slows the healing.
6.2. Pemphigus foliaceus
The wounds in the superficial forms of pemphigus differ greatly from those in pemphigus vul-
garis. These diseases present in such a superficial layer of the skin, that there is not enough tissue 
to trap fluid and allow for blister formation. The lesions present as many pruritic, crusted, coin-
sized patches on the upper torso, face and scalp (Figure 4). The skin had previously been healthy 
and the lesions have been described as “cornflakes”. These superficial crusts can be removed 
fairly easily, and will leave behind superficial erosions. If the lesions are not treated, they will 
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not heal and will only increase in number. In more severe cases of superficial pemphigus, the 
lesions can appear to merge and present similarly to exfoliative erythroderma, where the entire 
skin surface is affected. Oral involvement is uncommon in superficial forms of pemphigus.
The two clinical variants of pemphigus foliaceus, pemphigus erythematosus and fogo sel-
vagem also vary in their specific presentation. Pemphigus erythematosus tends to resemble 
lupus erythematosus in that it typically presents on the face in a butterfly distribution. In 
all forms of pemphigus, there are tissue-fixed intercellular deposits of antibodies. However, 
in pemphigus erythematosus, there are also often granular deposits of immunoglobulin or 
complement or both at the dermal-epidermal junction. As such, it is speculated that pemphi-
gus erythematosus might be a crossover syndrome between pemphigus foliaceus and discoid 
lupus erythematosus. However, it is important to note that granular deposits of immuno-
globulin or complement or both are not uncommon in normal sun exposed facial skin [1].
Fogo selvagem is histologically and immunologically identical to pemphigus foliaceus. The 
predominant difference is that it occurs in only certain rural areas in the world. Treatment 
for pemphigus foliaceus is similar to that for pemphigus vulgaris, requiring similar doses of 
drugs to control the disease. However, the prognosis is better for pemphigus foliaceus, due to 
the fact that the lesions are more superficial and there is therefore a smaller risk of infection, 
fluid loss and metabolic disturbance [1].
6.3. Wounds in bullous pemphigoid
Bullous pemphigoid has many different forms of its cutaneous presentation. There is a non-
bullous, prodromal phase of the disease, the signs and symptoms are not always specific 
Figure 4. Patient suffering from pemphigus foliaceous on back.
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to bullous pemphigoid. For example, there can be mild to severe intractable pruritus alone 
or in association with excoriated, eczematous, papular and/or urticarial lesions that may 
remain for several weeks or months. At this phase, the only sign of the disease may be these 
nonspecific cutaneous findings [12].
At the bullous stage of bullous pemphigoid, the patient develops vesicles and bullae on an 
urticarial base. They commonly also have urticarial and infiltrated papules and plaques, which 
can present in an annular or figurate pattern. Unlike in pemphigus, these blisters are tense. 
They range from 1 to 4 cm in diameter, are filled with a clear fluid and persist for several days 
(Figure 2). After they pop, they become eroded and crusted areas. Sometimes, the blister fluid 
becomes blood-tinged. Commonly, the lesions have symmetrical distribution patterns and they 
often present on the flexural aspects of the limbs and lower trunk, including the abdomen [12].
There are residual post inflammatory changes ranging from hyper- to hypopigmentation. 
Occasionally, milia appear as well (Figure 6). In 10–30% of patients, there is involvement of 
the oral cavity. Rarely, the mucosae of the eyes, nose, pharynx, esophagus and anogenital 
region are affected. Additionally, in about half of the patients, there is a peripheral blood 
eosinophilia.
6.4. Wounds in mucous membrane pemphigoid
The oral and conjunctival mucosae are the two most commonly involved sites for patients 
with this diagnosis. However, it is still possible for the disease to first appear in and affect 
any mucosal site, including the external genitalia, the anus, the upper aerodigestive tract and/
or the esophagus. Around 85% of patients with mucosal membrane pemphigoid have oral 
involvement and it is possible that the oral cavity is the only site of disease activity [13]. 
Figure 5. Epidermolysis bullosa acquisita patient with post inflammatory hyperpigmentation in annular pattern on legs.
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Within the oral cavity, lesions often involve the gingiva, buccal mucosa, and palate. It is less 
common to see lesions on the alveolar ridges, the tongue and the lips [1] (Figure 3).
Frequently, mucous membrane pemphigoid in the oral cavity presents as desquamative gin-
givitis along with bleeding erosions and paresthesia. In this case, it is rare to see small intact 
blisters. Sometimes, periodontal ligament damage and the loss of teeth may occur as a result 
of chronic inflammation. In certain parts of the mouth, transient vesicles can lead to chronic 
erosions. This can occur on the palate and is accompanied with variable pain. When there are 
lesions on the tongue, they are found on the lateral and ventral surfaces. Adhesions may form 
in the area of the uvula and tonsillar fossae as well as between the tongue and the floor or 
the mouth. After the lesions heal, they may become white reticulated striations, which look 
similar to lichen planus [1].
When the conjunctiva is affected, this can lead to blindness. Often, the conjunctiva is the only 
site affected. In most cases, lesions occur in both eyes, although the disease can begin unilater-
ally as well.
At the start of ocular involvement, there is nonspecific, chronic conjunctivitis, with burning, 
soreness, foreign-body sensation or mucus production. This conjunctivitis can either go into 
remission or become exacerbated, where it will progress to subepithelial conjunctival fibrosis [1].
It is rare to see conjunctival vesicles or blisters on the tarsal conjunctiva. Chronic inflammation 
is detrimental to the eyes and can lead to progressive scar tissue formation, shortened infe-
rior fornices, and symblepharon formation, which is adhesion between bulbar and palpebral 
conjunctival surfaces. Trichiasis, or inwardly angled eyelashes, and entropion, can also result 
Figure 6. Patient with milia on wrist, following treatment for bullous pemphigoid.
Autoimmune Bullous Diseases222
from conjunctival fibrosis. If the disease is not adequately controlled, trichiasis, entropion 
and xerosis (from scarring of lacrimal ducts) will lead to superficial corneal trauma, corneal 
neovascularization with subsequent corneal ulceration and blindness [7].
When the nasopharynx is involved, it is chronic and leads to extensive lesions of the upper 
aerodigestive tracts. The lesions lead to crusted ulcerations, epistaxis, fibrous adhesions 
between adjacent mucosal surfaces, and airway obstruction. When the pharynx is involved, 
there are typically ulcerations of the posterior or lateral pharynx and dysphagia. Laryngeal 
involvement is a potentially serious manifestation. It will present as hoarseness, loss of speech 
and can even lead to life-threatening stenosis, which requires tracheostomy [7].
While there is often dysphagia from the erosions of the esophageal mucosa, often esophageal 
disease can be asymptomatic. On the other hand, if there is chronic inflammation, it can lead 
to strictures and stenosis, with the associated dysphagia [7].
It is rare to see lesions on the genital and anal mucosa. However, when they appear, there are 
blisters and chronic erosions. In females, if there is progressive disease, it can lead to atrophic 
scarring and narrowing of the introitus. On the other hand, in male patients, adhesions can 
appear between the prepuce and the glans penis. When the anus is affected, it can result in 
anal scarring and in more severe cases, it can lead to stricture formation [7].
25–30% of patients with mucous membrane pemphigoid have skin involvement [7]. In this case, 
the lesions typically appear on the scalp, face, neck and upper trunk. These lesions differ from 
bullous pemphigoid in that they present as erythematous plaques, which lead to recurrent blis-
ter formation and erosions, with subsequent atrophic scarring. There are typically not too many 
lesions, but on occasion a patient can have bullous pemphigoid like clinical presentation [14].
In the Brunsting-Perry variant, skin lesions are only found on the head and neck region and 
mucosal involvement is typically minimal or absent. When the skin lesions are on the scalp, it 
can lead to scarring alopecia [33].
6.5. Wounds in epidermolysis bullosa acquisita
The presentation of epidermolysis bullosa acquisita is typical for a non-inflammatory mecha-
nobullous disease. Namely, these patients develop acral blisters that heal with atrophic scar-
ring, milia and hyper or hypopigmentation (Figure 5). Cutaneous blisters and subsequent 
erosions appear within non-inflamed skin or on areas of scarring. They are more frequently 
serous, but can also be hemorrhagic. They are typically found in more trauma-prone surfaces, 
including the elbows, knees and dorsal aspects of the hands, feet, and toes. Up to 20% of 
patients do have scalp involvement and extensive non-healing erosions with scarring alopecia 
have been noted in some cases [1].
6.6. General principles of wound care
Wound healing is a complex and active process that follows three consecutive phases. These 
include inflammation, tissue formation and tissue remodeling. In order for wound healing to 
be effective, there must be synchronization of not only cell–cell and cell-matrix interactions, 
but also interplay of cytokines to ensure successful communication among various processes. 
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The major players in this process include extracellular matrix proteins, cell surface receptors 
or integrins and growth factors. The extracellular matrix proteins have many functions, and 
bind directly to the cell surface receptors. As a result, they determine the effects of growth 
factors, such as TGF-beta, on cells [1].
While injured fetal tissue has the capacity to regenerate, or heal completely without fibrosis, 
injured tissue in children and adults still follows a reparative process, but can lead to fibrosis. 
There are many systemic diseases, including diabetes mellitus and atherosclerosis, as well 
as more local factors, such as pressure and infection, that can lead to chronic non-healing 
wounds [4].
When an injury occurs, it is critical to restore skin integrity and homeostasis. Therefore, the 
main goal of wound healing response is to quickly reform a functional skin barrier. The best 
wound healing response would be if there was complete regeneration of skin tissue and its 
adnexal structures. Ideally, original skin function and morphology would be completely 
restored. However, this is often not the final result of wound repair and there are variable 
responses in how skin tissue reforms [4].
6.7. Regeneration versus repair
In wound healing response, a distinction must be made between regeneration and repair. 
The wound healing responses follows repair more than regeneration. In other words, the skin 
barrier is not restored to its pre-injured state, but rather leads to fibrosis or scar formation. 
Additionally, adnexal structures, including hair follicles, sweat and sebaceous glands, and 
components of the dermal extracellular matrix may not regenerate. As a result, there is a loss 
of normal skin function and impaired morphology [15].
Regeneration can occur during embryogenesis to injured fetal skin. It is able to heal com-
pletely without fibrosis. Research has indicated that fibromodulin, a small leucine rich pro-
teoglycan, is thought to mediate scarless fetal skin wound repair [15]. It is thought that this 
process partly works via transforming-growth factor- beta modulation. A research study 
showed that when fibromodulin−/− mice were compared to wild type mice, they were 
found to have delayed wound closure and a large increase in scar size. When they were 
later administered exogenous fibromodulin, there was improvement in wound closure and 
scar size [15].
6.8. Effect of immune response on wound healing
The immune system, and its major players, including neutrophils and macrophages hold a 
key role in wound healing. Inflammation influences the repair process and can affect the 
quality of the wound and the extent of scarring. Many repair models have shown that there 
is an inverse correlation between the strength of the inflammatory response and the ability to 
undergo regeneration. Namely, it appears that when the inflammatory immune response is 
greater, there is more inappropriate wound repair [16].
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6.9. Insights from animals on the immune system and wound healing
Amphibians and fish are unique in their ability to regenerate anatomically complete and fully 
functional tissues and organs. Specifically, urodele amphibians (newts and salamanders) can 
regenerate a range of organs and tissues [17]. This occurs in a process in which there is dedif-
ferentiation of cells at the site of amputation injury, followed by their proliferation to produce a 
blastemal that finally reforms the missing tissue. It is postulated that the ability to regenerate is 
related to the fact that the regenerative response induces minimal inflammation. However, fur-
ther investigation is needed to elucidate the role of inflammation in the regenerative response [1].
Furthermore, zebrafish are able to regenerate their entire caudal fin, even as adults, including 
the original pigment and color structures [18]. However, in this process, regeneration occurs 
in the presence of inflammation since there is an infiltration of myeloid inflammatory cells 
early on. When an experiment knocked out the gene responsible for myeloid cell develop-
ment and the inflammatory response, there was no effect on fin regeneration [19]. Therefore, 
future research must examine whether there is a relationship between fin regeneration in 
zebrafish and the inflammatory response.
In mammals, such as mice and humans, the effects of inflammation on regeneration and 
repair have also been studied. In children and adults, wound repair results in scar formation. 
However, injured fetal skin is able to fully regenerate in a scarless manner [20]. It is noted that 
a major difference between fetal and post-natal skin is that there is a lack of significant inflam-
mation in fetal skin post injury. Additionally, there is a difference in the extracellular matrix, 
cellular mediators, gene expression profiles as revealed by transplantation experiments, as 
well as unknown factors intrinsic to fetal skin [21].
There have been experiments using transgenic mice to learn more about wound healing. When 
mice were lacking nidogen 1, a basement membrane component, or TGF-beta, there was delayed 
wound healing [22]. Additionally, there was delayed wound healing in mice with a fibroblast-
specific deletion of integrin B1, which binds extracellular matrix proteins, in mice that lack 
superoxide dismutase, an important ant oxidative enzyme, or IL-6 in mice that lack Toll-like 
Receptor 3, and have a defective recruitment of neutrophils and macrophages [23]. When mice 
lack matrix metalloproteinases, which degrade extracellular matrix proteins, or when mice are 
deficient in Natural Killer (NK) or T Cells, there is accelerated wound healing [24].
6.10. Wound depth and wound healing
Different terminology is used to describe a wound, depending on its depth. Wounds are cat-
egorized as erosions when they only affect the epidermis. However, when the wound extends 
into the dermis, it is referred to as ulceration. Partial thickness wounds are when the epidermis 
and portions of the dermis are missing, and the ulcer extends into the mid dermis. In partial 
thickness wounds, adnexal structures remain. On the other hand, in full thickness wounds, the 
entire dermis is involved, and the wound extends into the subcutaneous fat. In these wounds, 
adnexal structures are lost as a source of keratinocytes necessary for reepithelization [1].
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The extent to which the skin can repair or regenerate is dependent on the depth of the skin 
injury. For example, erosions are the least severe of the wounds mentioned above. When they 
heal, the entire epidermis is able to regenerate, and here is no scarring. On the other hand, 
ulcerations heal via a reparative, not a regenerative process, and are therefore associated with 
scar formation [1].
As mentioned above, in partial-thickness wounds, the preserved adnexal structures serve as 
a source of epithelial to repopulate the epidermis [25]. Specifically, epithelia from these struc-
tures and the wound edge migrate across the wound surface to provide full coverage.
However, in full thickness wounds, where adnexal structures are lost, the reepithelializa-
tion can only occur from the wound edges [26]. As a result, healing of full-thickness wounds 
includes contraction. While the mechanism of contraction in wound healing is not fully eluci-
dated, it is believed that contraction may be mediated by mechanical or biologic factors, such 
as differentiation of fibroblasts into myofibroblasts. During contraction, there is centripetal 
movement of pre-existing tissue, rather than formation of new tissue.
6.11. Cellular and molecular aspects of skin repair
Numerous cell types interact during the repair response. These include cells that reside in the 
tissues, such as keratinocytes, endothelial cells, and fibroblasts, as well as hematopoietic cells 
that are recruited to the site of tissue damage. These cell types all interact during the three 
phases of wound repair [27].
6.12. Inflammatory phase
The first phase of wound repair is the hemostasis and inflammatory phase. When tissue injury 
occurs, there is extravasation of blood into the wound and eventual clot formation. The clot 
is comprised of collagen, platelets, thrombin and fibronectin. These factors release cytokines 
and growth factors that initiate the immune response [28].
Then, there is local activation of innate immune functions and chemoattraction. Both of 
these processes result in an early influx of polymorphonuclear leukocytes or neutrophils. 
Neutrophils destroy bacteria by releasing caustic proteolytic enzymes. Next, there is an 
invasion of blood monocytes, which differentiate into tissue macrophages. Activated mac-
rophages clear the wound of dead neutrophils, bacteria and debris, as well as release many 
cytokines necessary for angiogenesis, such as VEGF, TGF-Beta, and platelet derived growth 
factor. As inflammation progresses, the number of neutrophils decline, while the number of 
macrophages increase [28].
6.13. Proliferative phase
The release of cytokines and growth factors is necessary for the initiation of the proliferative 
phase. In this phase, invading macrophages, fibroblasts and endothelial cells make up newly 
formed granulation tissue. Many proteins such as fibrin, fibronectin, vitronectin, collagen III 
and tenascin are components of the provisional extracellular wound matrix which enable cell 
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adhesion, migration and proliferation. There are also epidermal-mesenchymal interactions at 
the wound edge, which stimulate keratinocyte proliferation and migration, and ultimately 
lead to reepithelization [29].
6.14. Remodeling (maturation) phase
After epithelization is complete and cell proliferation and neovascularization stop, scar tissue 
forms and the wound enters the remodeling phase. This phase lasts several months and is 
described by a balance between the synthesis of new components of scar matrix and their deg-
radation by proteases. The degree of balance between the two processes determines whether 
there is normal or abnormal scar formation. Abnormal scar formation includes atrophic scars, 
hypertrophic scars and keloids. The exact mechanism of how granulation tissue regresses and 
transforms into scar tissue is still not completely known [30].
In addition to the scar tissue formation, there is also regression of vascular structures, trans-
formation of fibroblasts into myofibroblasts, substitution of provisional extracellular matrix 
with a permanent collagenous matrix and a final act of the inflammatory response. The exact 
mechanism of this step is still not known [31].
6.15. Wound healing and aging
There are two main mechanisms which are related to human aging. These include telomere 
shortening and DNA damage. When telomere shortening or dysfunction occurs, there is 
instability of chromosomes. In a study examining telomerase-deficient mice, impaired wound 
healing was noted. Additionally, when mice had increased activation of the transcription fac-
tor p53 within the epidermis, they developed an early aging phenotype of their skin and 
impaired wound healing [32].
6.16. Wound healing and immunosuppressants
Immunosuppressive therapy is used to treat immunobullous disease. Depending on the spe-
cific immunosuppressive treatment, wound healing is affected to different degrees.
Wound healing is a complicated process involving many different cells, hormones, cytokines, 
proteases and growth factors. Additionally, these can be broken into four phases: hemostasis, 
inflammation, proliferation and remodeling, which are each essential for adequate wound are 
healing. Research demonstrates that immunosuppressive agents that are used in conditions 
such as organ transplant and IBD have been shown to impair the wound healing process [33] 
(Table 2).
6.17. Several inflammatory mediators involved in the wound healing process are 
affected
Immunosuppressants affect several inflammatory mediators involved in the wound-healing 
process. These include IL-2, IL-4, IFN-gamma, TNF, alpha, and GM-CSF. At the outset, IL-2 
activates macrophages, T cells, NK cells and lymphokine-activated B cells and T cells. IL-4 
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stimulates fibroblast proliferation early in the wound healing process and later on downregu-
lates cytokine expression. IFN-gamma and TNF-alpha are both leukocyte chemoattractants. 
In addition, IFN gamma, along with GM-CSF, is a leukocyte activator [33].
6.18. Modes of action of immunosuppressant drugs
6.18.1. Systemic steroids
Systemic steroids are chemical modifications of natural glucocorticoids. The most commonly 
used systemic steroids include prednisone and prednisolone. To become active, prednisone is 
converted to prednisolone by modifying the 11-keto group to become an 11-hydroxyl group. 
The glucocorticoid activity of prednisone and prednisolone is 3–4 fold greater than hydrocor-
tisone. Corticosteroids alter lymphocyte recirculation and create a transient lymphocytope-
nia. They also induce lymphocyte death. The most important immunosuppressive effect of 
corticosteroids is inhibiting cytokines, which further prevents T cell activation [37].
6.18.2. Azathioprine
Azathioprine is the 1-methyl-4-nitro-5-imidazolyl derivative of 6-MP. AZA and is metabo-
lites suppress intracellular inosinic acid synthesis, which interferes with intracellular purine 
synthesis. This drug leads to a reduction in the number of circulating B and T lymphocytes, 
which results in decreased immunoglobulin production and reduced IL-2 secretion [33].
Author(s) Drug(s) under 
investigation






MMF, SLR, everolimus, 




Tacrolimus less likely to cause 
collections or bleeding (p < 0.05 
and p = 0.02)
Lymphocoeles more common in 
mammalian target of rapamycin-
inhibitor regimens (p = 0.012)
Valente 
et al. [35]
MMF, SLR Retrospective Abdominal 
wounds
Incidence of wound complications 
2.4% (MMF group) compared 
with 43.2% (SLR group) 
(p < 0.0001)
Grim et al. 
[27]
SLR, MMF, steroid and 




31.8% in the SLR group developed 
wound complications compared 
with 14.3% in the tacrolimus 
group (p = 0.0163)
Selman 
et al. [36]
Rituximab Prospective A linear dorsal 
incision in mice
The results yield that the wound 
healing significantly decreased 
(p < 0.05) in Groups 2 and 3, 
which received Rituximab, as 
compared to control group.
Table 2. Role of immunosuppressive drugs in wound healing.
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Stolzenburg et al. studied the effect of Azathioprine on anastomotic healing in rats. There 
were 48 Wilstar rats divided into groups of four per cage, then randomized into three groups 
receiving one daily dose of placebo, low dose, Azathioprine, and high dose Azathioprine. 
There were no significant differences in wound healing between the three groups [33].
6.18.3. Mycophenolate mofetil
Mycophenolate mofetil (MMF) is an ester of an old drug, mycophenolic acid. It is an anti-
metabolite agent that interrupts purine metabolism in T and B lymphocytes. It inhibits the 
generation of cytotoxic T cells and the rejection of allogeneic cells. Research has shown that it 
can suppress the formation of antibodies against alloantigens in a chronic rejection model and 
that it can abolish the formation of antibodies against xenogeneic cells [33].
There have been some animal studies performed to look into the effect of mycophenolate 
mofetil on the healing of left-sided colon anastomosis in Sprague-Dawley rats. This study 
showed that MMF inhibits injury induced reparative proliferation of colonic mucosal cells. 
The bioavailability of MMF in humans is nearly 100% and pharmacokinetic measures are 
similar in humans and rats [33].
6.18.4. Rituximab and wound healing
Rituximab binds to the CD20 antigen found on the surface of all B-lymphocytes, it lyses 
the cells and activates complement. In all cases in which rituximab is given, there is a rapid 
decrease of circulating B-cells. B-cell recovery does not begin until 6–9 months after comple-
tion of treatment [38].
Rituximab delays wound healing in male mice and that further research is needed to study 
the direct effects of the drug on wound healing in humans [38].
There is a clear correlation between immunosuppressive agents, inflammatory mediators 
and the wound-healing process. This complicates treatment of autoimmune bullous diseases 
where immunosuppressant therapy is required to treat the underlying condition [33].
7. Wound dressings
Currently, there are many different wound dressings available. However, the specific type of 
dressing depends on characteristics of the wound. While clinical trials have examined the effi-
cacy of different dressings for a variety of wounds, clinical experience has ultimately shaped 
most of the recommendations.
The commonly accepted mechanism of action of wound dressings is to support wound heal-
ing by acting as a barrier between the wound and the environment, by preventing drying of 
the tissue or autolytic debridement. There are some dressings which actually interfere with 
cellular and molecular mechanisms of the wound microenvironment, and counteract mecha-
nisms that are considered incompatible with wound repair [39].
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8. Role of growth factors
Growth factors help to regulate cell function during wound repair. Therefore, topical applica-
tion of many growth factors can modify and even accelerate wound repair.
Platelet-derived growth factor (PDGF-BB) is the first and only recombinant growth factor 
to be effective and approved for the topical treatment of diabetic foot ulcers [40]. Currently, 
there is promise in the use of perilesional injections of granulocyte-macrophage colony-stim-
ulating factor (GM-CSF). Wankell et al. showed that in transgenic mice, where an antagonist 
of GM-CSF was overexpressed in the epidermis, delayed wound healing was observed [41]. 
However, further studies must be conducted to further explore the efficacy of this treatment.
There is promise in a combined molecular and genetic approach. Ideally, genetically modified 
cells would synthesize and deliver the desired growth factor in a time-regulated and locally 
restricted manner to the wound site. This would overcome some of the limitations that are 
faced in the local application of recombinant growth factors [42].
9. Composition of a dressing
The exact composition of a dressing is an important factor in the decision process. It should 
be made of an inert material, which will not shed fibers or compounds into the wound. If the 
material is not inert, a foreign body or irritant can enter the wound and lead to an immune 
response.
A critical aspect of a wound dressing is the capacity to maintain a moist environment. 
Moisture assists the reparative process, by suppressing tissue desiccation and crust forma-
tion. If a wound is left to dry, a scab or eschar will form. This specifically occurs in the super-
ficial dermis, which actually becomes integrated into the scab itself [1].
In 1962, there was a study conducted by George Winter that looked at moist wound healing. 
It demonstrated a 30% greater benefit of occlusive dressings versus air drying of wounds. 
There have been subsequent studies since Winter’s work that further demonstrate the benefit 
of moist wound healing by occlusive dressings [31].
Winter and Scales conducted studies examining the effects of leaving wounds uncovered. 
They found that air dried wounds developed thicker scabs and reepithelialized at a slower 
rate. This is due to the fact that when the wound is air dried, the regenerating epidermis must 
migrate deeper below the dry fibrous tissue to a region of moisture where live cells survive. 
It is only in such an environment where epidermal cells are able to move toward bridging 
the defect of the wound. The thickness of the wound correlates with the deepness of the 
migration of the regenerating epidermis. The thickness of the wound in addition to the con-
tinuing loss of dermis and collagen and a reduction in adnexal structures, contributes to the 
depth of the scars and to a worse cosmetic outcome [31]. Therefore in the case of pemphigus 
and pemphigoid, the superficial depth lends itself to compute healing without scarring. The 
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predictable depth of these erosions is intraepidermal in the case of pemphigus vulgaris and at 
the dermis epidermal junction in bullous pemphigoid.
Furthermore, there are many endogenous factors that are essential for proper wound healing 
that are found in fluid from occluded acute cutaneous wounds that may be more available in 
a moist environment [31].
Finally, it is believed that moist wound healing environment has the ability to confer an elec-
trical gradient between the wound and normal skin. Following injury of the skin, there is an 
internal battery and a current flow created until drying of the wound occurs. By maintain-
ing the moisture, the electrical gradient may promote epidermal cell migration between the 
wound and the surrounding skin [39].
10. The role of oxygen in wound healing
The requirement for oxygen differs based on the stage of wound repair. Studies have shown 
that the oxygen requirement is low in the early wound repair stages. Following acute injury, 
there is a disruption of blood flow from clotting that prevents exsanguination. This leads to a 
temporary but extreme hypoxia, which is a signals the migration of keratinocytes and fibro-
blasts as well as the initiation of angiogenesis [43].
Additionally, studies have shown that hypoxia upregulates proliferation and production of 
TGF-Beta by dermal fibroblasts. Then, TGF-Beta stimulates production of extracellular matrix 
molecules. It is also noted that hypoxia allows keratinocytes to migrate better along keratin 
and fibronectin, and that low oxygen levels promote angiogenesis in the acute wound [43].
Therefore, the use of semipermeable dressings has been promoted to allow the appropriate 
oxygen tension for wound repair to proceed quickly. When acute wounds have been allowed 
to heal under occlusion, they have shown accelerated healing, greater resistance to breaking 
open, as well as better cosmetic outcomes than those that heal open to the air [44].
11. Traditional wound dressings
Traditionally, wound dressings have been composed of natural, synthetic or partially syn-
thetic materials. Cotton, silk, linen or cellulose-based substances are naturally occurring mate-
rials that have been produced in many combinations to maximize clinical usefulness. Today, 
the basic cotton gauze dressing is composed of cotton plus cellulose acetate. The cellulose 
acetate is added to enhance the absorbency [1].
Different manufacturers incorporate various substances into the fabric. These include white 
petrolatum and other ointments, including paraffin wax (Vaseline gauze, aquaphor gauze), 
and can also include antibacterials such as povidone-iodine, sulfadiazine, bismuth, framyce-
tin and chlorhexidine. Medicated dressings are frequently used for malodorous wounds such 
Wound Care in Immunobullous Disease
http://dx.doi.org/10.5772/intechopen.71937
231
as chronic ulcers, and are made of rayon, nylon or gauze. Activated charcoal cloth with or 
without antibacterial silver salt is also used for exudate absorption as well as odor control [1].
Traditional wound dressings are placed immediately against the wound bed and have multi-
ple advantages. These include the advantage of having less chance of adhering to the wound. 
The main disadvantage of this type of dressing is the potential for maceration of the wound 
and surrounding skin if the dressing stays in place for an extended period of time [39].
While traditional dressings are relatively inexpensive and readily available, they require fre-
quent replacement. This can be time consuming for both the patient and the medical staff. 
Therefore, traditional dressings are potentially costly in terms of the time required for health-
care personnel [44].
12. Technique for most conventional dressings
Currently, most dressings are layered and either qualifies as “pressure” or “non-pressure” 
dressings. A layered dressing is usually composed of three parts. There is a contact or inter-
face layer, which is typically a non-adherent, fluid permeable material, which makes direct 
contact with the wound. Next, there is the absorbent layer. This is normally a cotton pad, 
gauze or other material. It is placed directly on top of the contact layer to “wick-in” and retain 
wound exudate. This also allows the dressing to mold to the shape of the wound. Finally, 
there is an outer layer or wrap, which is often tape or another banding material, such as a self-
adhesive bandage. Its purpose is to retain the underlying layers. It is essential that each layer 
is placed in close approximation to the one before it, without air pockets. Each layer should 
also increase in size and degree of overlap from the wound to the outermost layer [1].
13. The use of antimicrobial agents in wound dressings
There is debate regarding the usefulness of topical antimicrobial agents for cutaneous 
wounds. It is believed that in the absence of infection, a topical antimicrobial is not necessary 
as well as the wound is taken care of well. However, there is evidence that infection prolongs 
wound healing. Therefore, there is the need to distinguish between bacterial colonization of 
the wound and true infection that actually compromises the tissue [1].
14. The use of silver and iodine to control wound infection
Many dressings incorporate compounds such as silver and iodine to control infection. Silver 
is an anion with strong antimicrobial activity. Therefore, it has been used for decades to treat 
wound infections. The mechanism by which silver ions kill microorganisms is by inhibit-
ing bacterial-specific enzymes that are important in bacterial cell wall synthesis and gene 
transcription. There is evidence that silver-containing dressings considerably decrease the 
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incidence of burn wound –associated sepsis and bacteremia as well as shorten hospitalization 
time. Additionally, silver ions reduce the levels of matrix metalloproteinases that are upregu-
lated in non-healing wounds [28].
15. Silver-containing dressings
At the original introduction of silver-containing dressings, silver ions were present in the form 
of silver nitrate and silver sulfadiazine. However, newer formulations are composed of high 
density polyethylene mesh that is impregnated with nanocrystalline silver. Acticoat, Actisorb 
Silver, Contreet Foam, Contreet Hydrocolloid and Silverlon and examples of nanocrystalline 
silver dressings [45].
These dressings offer antibiotic activity against both gram-positive and gram-negative bac-
teria. Each of these dressings is able to release antibacterial levels of silver for 3–7 days. 
Research has indicated that silver impregnated dressings can enhance the short-term healing 
of wounds and ulcers [1].
However, recent studies have shown, that in certain patient populations, the use of silver-
containing dressings is contraindicated due to potential toxicity. These include, patients with 
surgical wounds that are at low risk for infection, pregnant or lactating women, patients who 
are sensitive or allergic to silver or metals, patients with wounds being treated with an enzy-
matic debridement agent, patients with wounds that have no signs and symptoms of infection 
present, chronic wounds that are healing as expected, patients with wounds in or near sites 
that are being treated or have been treated with radiotherapy, patients with wounds in which 
slough or necrotic tissue is present, as well as wounds that are colonized with multiple organ-
isms or biofilms [46].
Additionally, there have been reports of silver toxicity in the setting of treating large-surface-
area wounds with silver impregnated dressings. Therefore, silver toxicity should be consid-
ered when patients present with leukopenia [47].
16. Use of iodine in wound dressing
Iodine has been used to help with wound healing for over 150 years [48]. Povidone-iodine is a 
frequently used antiseptic which can actually inhibit wound healing [49]. However, there are 
newer dressings, such as cadexomer-iodine polymer that slowly release iodine from dextran 
beads. These do not appear to have toxic effects on keratinocytes. In this dressing, there is a 
low level of iodine that is slowly released from the beads.
Iodine wound dressings are recommended for exudative wounds, including leg ulcers and 
are not appropriate in the treatment of autoimmune bullous disease. Caution must be taken 
when using these dressings in patients with a history of thyroid disease. These dressings 
should be avoided in young children, pregnant or lactating women or patients with a known 
or suspected iodine insensitivity [49].
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17. Recommended wound care in immunobullous disease
17.1. Treatment of pemphigus vulgaris, pemphigoid and Steven Johnson syndrome 
in a burn unit
Steven-Johnsons syndrome, toxic epidermal necrosis, pemphigus vulgaris and bullous pem-
phigoid display disruption of the skin layers or its blood supply and produce similar lesions 
that mimic a burn injury. When greater than 60% of total body surface area is involved, it is 
recommended that patients are admitted to a burn care unit. In the unit, these patients are 
provided with a proper environment, temperature, humidity and infrared lamps to prevent 
infection. High mortality and morbidity are reduced by proper handling and hospitalization 
in a burn care unit. Wound management in these diseases require similar care to burns, as 
well as fluid resuscitation and dietary care [50].
17.2. General nursing care pemphigus and pemphigoid
The best approach to the care of blistered skin has not yet been definitively established. There 
is currently controversy on how to deal with small tense blisters. While some resources recom-
mend daily rupturing of tense blisters for reducing lateral extension of the blister edges, other 
resources advocate for leaving blisters intact, to prevent secondary infection. However, large 
blisters should be aspirated with a sterile needle, to keep the blister roof in place. Raw areas 
need to be cleaned by antiseptics or normal saline and then covered by a non-adhesive dress-
ing. Excessive skin manipulation and trauma should be avoided in active pemphigus vulgaris 
[51]. When patients have oral mucosal lesions, it is recommended them to maintain a soft diet, 
use soft tooth brushes, antiseptic gargles and prophylaxis against oral candidiasis [52].
The wound care in treating pemphigus vulgaris and bullous pemphigoid depends on the 
severity of the disease, the location of the lesions, as well as the total body surface area (TBSA) 
covered with lesions. While there have been several case studies published with different 
recommendations regarding wound care, each is individualized to the unique needs of the 
specific patient, and there is not yet one specific standard of care [52].
When patients who have extensive raw areas are hospitalized, they must be isolated to 
reduce cross-infection. Secondary bacterial (MRSA, pseudomonas) or viral (HSV) infections 
can occur. The use of antimicrobials is effective. Additionally, it is important to routinely 
monitor blood pressure and blood glucose levels. Steroid related complications frequently 
occur shortly or within 1 year of the start of systemic treatment in bullous pemphigoid. These 
include infection, worsening of diabetes or blood pressure, and pressure sores. These com-
plications must be monitored so that the immunosuppressant dose can be adjusted if needed 
[53]. After prolonged hospitalization, MRSA colonization can occur. Additionally, a five-day 
decontamination regime with 4% chlorhexidine body wash and nasal mupirocin ointment 
may be considered when lesions resolve [51].
Typically, hospitalized patients with bullous pemphigoid have multiple comorbidities, and 
often present with generalized involvement, a more severe disease, recurrent relapses, higher 
morbidity and mortality. This occurs especially in the first year. Patients typically have a worse 
prognosis when they are bed bound, anemic, hypoalbuminemic or have a malignancy [51].
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17.3. Severe disease
In severe disease, the premise of care is very similar to patients being treated for partial thick-
ness burn therapy. Frequently in pemphigus vulgaris and bullous pemphigoid, the body is 
covered with intact bullae and partial-thickness wounds from head to toe. Serous sanguine-
ous fluid drains onto the linens, which exacerbates pain since once it dries it becomes stuck 
and unstuck to bed sheets and bandages [54] (Figure 7).
In severe pemphigus and pemphigoid, various goals of wound care management have been 
identified. These include relieving severe pain, preventing infection and decreasing biobur-
den, enhancing regeneration of the dermis and the epidermis, protecting the periwound skin 
from maceration, encouraging patient mobility and quality of life, providing nutritional sup-
port for tissue repair, as well as treating the underlying cause of the wound [55].
All dressing products used for these patients must be nonadherent. Following chemotherapy 
for severe lymphocytic leukemia, a 66 year old female with pemphigus vulgaris was given a 
daily dressing which utilized a foaming skin care wash [56]. Additionally, there was a non-
sting barrier to protect the intact skin and hydrogel sheets to provide a moist environment. An 
advanced ionized silver wound-care product in the form of a gel or powder was considered 
given the possibility of wound infection. Xerofoam gauze is an optimal product to add over 
the hydrogel sheet to prevent it from drying out and to stabilize it. At the start of the wound 
care, large abdominal dressings were also applied over the Xerofoam gauze to absorb the 
drainage. Above that, various kinds of stretch bandages or nets were placed to secure the 
Figure 7. Pemphigus vulgaris lesions on patient’s leg.
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dressing [54]. It is important to keep the skin surface moist and not open to air for healing and 
pain management.
Ultimately, the wound care plan focuses on reducing pain, preventing infection by gentle 
cleansing and preventing scarring by providing a moist environment. Additionally, nutrition 
is a key aspect of care, due to the loss of protein and other essential components in the serous 
sanguineous drainage [51] (Table 3).
17.4. Silver containing hydrofiber dressings for pemphigus vulgaris wounds
Recent studies have advocated for the use of silver-containing hydrofiber dressings as effective 
adjunct in the treatment of pemphigus vulgaris. Following the application of these dressings, 
1. Clean the wound
a. Use a foaming skin care wash (Cetaphil or Cerave)
i. allows cleaning of the wound without pain, it is nonabrasive
a. Apply directly to wounds and then gently rinse off
b. Shower
c. Wrap in a warm bath blanket to maintain temperature, which is conducive to wound healing
2. Protect the periwound skin
a. “No-sting” skin barrier similar to applying a thin film on the intact skin as a shield against excessive moisture
a. No-sting is painless because alcohol is not an ingredient
i. Spray (StingFree)
ii. Pad (StingFree)
3. Provide a moist environment
a. Hydrogel sheet
i. Gelled water formed into a flat dressing
ii. 4 × 4 or 6 × 8 inches
b.  Cover wound with film with the sticky side placed on the wound bed
4.  Optional step: placement of a fine mesh nonadherent gauze which is impregnated with petrolatum and 3% 
bismuth tribomophenate
a.  the gauze secures the hydrogel and provides additional protection of the periwound skin
5.  Optional step: If wound drainage is excessive, then heavy ABD pads (cotton dressing pads) can be applied to 
wick away the drainage
6.  Secure dressing with Kerlix, a conforming, 100% woven gauze
7.  A self-adhesive wrap with minimal stretch provides the finishing touch to the dressing, allowing the patient 
mobility and improved quality of life
Table 3. Wound care plan [55].
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there was marked improvement in wound healing and decreased patient discomfort [45]. 
Additionally, topical measures such as hydrotherapy, topical glucocorticoids and topical 
antimicrobial agents also help to control the disease. Unfortunately, some patients are resis-
tant to these conventional therapies. Previous studies have supported the use of silver con-
taining hydrofiber dressing patches (SHD) for managing partial thickness burns and toxic 
epidermal necrolysis [45].
SHD is made from the hydrocolloid polymer carboxymethylcellulose to which silver ions are 
attached. The dressing fibers absorb wound exudate and swell to form a soft cohesive gel that 
covers the wound surface. It has the ability to absorb large volumes of exudate, up to 20 times 
its weight in fluid. Therefore, it is suitable for heavy exudating wounds. Since it retains fluid 
in the dressing over the wound, it dehydrates less quickly than other dressings and promotes 
a moist healing environment. Additionally, it limits lateral movement of fluid and avoids 
maceration of the surrounding skin [45].
A recent case of pemphigus vulgaris involving 62% of the total body surface area (TBSA), exam-
ined the effectiveness of SHD for wound healing [45]. Following the use of SHD, the patient 
showed dramatic wound healing with reduced patient discomfort. Specifically, after starting 
the SHD therapy, there was a marked improvement in wound healing and the affected TBSA 
decreased from 62–5% over just 4 weeks. After just 1 week after starting the SHD therapy, 
no new skin lesions were noted. Not only did this treatment appear to be effective in wound 
healing, but it is also less time consuming. Dressing changes only took 45 minutes every 3 
days with SHD, compared with 2 hours every day with hydrotherapy and SSD care. It was 
also noted that the patient experienced less pain and discomfort during the dressing changes.
17.5. The use of nano-silver dressings (Acticoat) in pemphigus vulgaris
As stated above, over the past three decades, nanocrystalline silver dressings have provided 
antimicrobial, pro-healing, and anti-inflammatory activity. Antibacterial effects have mini-
mized the frequency of wound dressing and have improved the healing of acute and chronic 
lesions from superficial to deep layers. Acticoat is a silver biologic dressing containing a 15 nm 
bactericidal coat of nanocrystallized ions of silver in a cluster structure. It coats many cells 
that are exposed to infection and protects them through continuous silver ion release. Acticoat 
is able to eliminate at least 150 types of microorganisms after 30 min of use. Nanocrystaline 
skin dressings have been found to be beneficial in many skin lesions, including burns. It has 
also been found that compared with traditional wound dressings such as silver sulfadiazine, 
nanocrystalline coated silver dressings not only have shortened hospital stays and less fre-
quency of wound dressing changes, but there is also improved wound healing and balancing 
overall costs, in addition to a higher satisfaction rate by patients [57].
Masjedi et al. compared a nanocrystalline silver dressing with a regular sulfadiazine nor-
mal dressing (the control) in the treatment of pemphigus vulgaris lesions [58]. 16 patients 
each received both an experimental and control dressing on symmetrical lesions. Qualitative 
wound score (QWS) and clinical photography were conducted during treatment for 4 weeks. 
After 4 weeks, QWS decreased by 1.94 more in the experimental compared to baseline than in 
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the control group. Ultimately, after 4 weeks, QWS decreased by 1.95 more in the experimental 
compared to baseline than in the control group. Additionally, after 4 weeks, Acticoat showed 
complete healing in 13 cases in addition to one acceptable healing. It was also noted that 
Acticoat shortened hospital stay and provided easier handling. While this study showed that 
the nanocrystalline silver dressing, Acticoat was superior to the silver sulfadiazine dressing 
in treating vesicobullous lesions, there still has not been a trial which examined the effect of 
this dressing on wound healing time without superinfection and on costs and complications.
17.6. The use of banana leaf for wound management of patients with toxic 
epidermal necrolysis
Steven Johnsons Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are life-threatening 
allergic reactions usually to medications, which require immediate treatment. These two 
diseases can be differentiated by the surface area affected by epidermal necrosis. SJS only 
involves skin lesions on less than 10% of the total body surface area, whereas TEN involves 
10–30% skin lesions with severe inflammation of mucosal tissues.
The main goal is to prevent infection and to encourage healing. Wound care for these diseases 
is similar to severe cases of pemphigus vulgaris and bullous pemphigoid.
Modern medical supplies for wound management include paraffin coated mesh, Vaseline, 
petroleum, disinfectant dressings with silver-compounds such as nanocrystalline silver dress-
ing, silver hydrofiber, as well as silicone silver foam dressing. These dressings are all very 
expensive, and efforts must be made to find dressings, which reduce cost as well as pain level.
Recent studies have found that using aloe vera resulted in better healing rate than silver sul-
fadiazine (SSD) [59]. Additional studies have explored using honey dressing on burns and 
found that they resulted in better healing and lower rate of necrosis compared to SSD [60]. In 
a comparative study between boiled potato peel bandages and sterile banana leaf, there were 
similar healing rates between the two, but the banana leaf was more cost effective and did not 
cling to the wound as much [61].
Uppanisakorn et al. examined the use of a sterile banana leaf dressing, which allowed the 
patient to be discharged swiftly and reduced the cost of treatment by eight times. When sup-
portive therapy using banana leaf dressing was given, the patient was able to be discharged 
within 12 days [62].
There is much promise in the use of sterile banana leaf dressings for wound management. The 
price is 160 times lower than the cost of paraffin gauze. It has also been known to decrease 
pain and increase ease and speed of wound healing. The only caution of using banana leaf 
dressings is the potential for infection from contamination.
Further research must be done to determine the efficacy of banana leaf dressings for patients 
with pemphigus and pemphigoid.
17.7. Pemphigoid wound care – specific considerations
Pemphigoid most frequently affects elderly adults. As a result, these patients are frequently 
dependent upon relatives or health care workers for personal care activities. Therefore, their 
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ability to comply with treatment must be considered. Topical corticosteroid therapy is not a 
favorable option for patients who are unable to properly apply the medication and lack access 
to assistance. In this patient population, a combination of comorbidities and adverse effects 
of treatment, rather than the direct effects of disease, are what actually lead to morbidity and 
mortality. Treatment should be conservative and a minimal amount of medication required 
to achieve remission should be given [50].
While a high potency topical corticosteroid is often used for patients with bullous pemphi-
goid, if the patients are unable to properly administer topical treatment, a systemic gluco-
corticoid will be required. These are typically more accessible to patients at a lower cost, and 
have increased compliance. In addition, often when patients have widespread involvement, 
systemic therapy is faster and easier to administer than topical therapy [63].
17.8. Mucosal wound care
Oral blisters in pemphigus vulgaris have a very thin roof and rupture as a result of oral traumas, 
which leads to multiple chronic painful bleeding ulcers and erosions that heal with difficulty 
(Figure 8). There are patient reports of pain in the oral cavity as well as a burning sensation that 
occurs when they consume spicy or acidic foods. While blisters can appear at any localization of 
the oral mucosa, they most frequently appear in sites that are subjected to friction, including the 
soft palate, buccal mucosa, ventral tongue, gingiva, and lower lip. Infrequently, there are lesions 
on the gingiva [64]. In more advanced stages of pemphigus vulgaris, desquamative or erosive 
gingivitis can be observed. There are other oral manifestations, including sialorrhea, halitosis 
and the continuous formation of brown or blackish crusts at the vermillion border. Pemphigus 
vulgaris can involve the conjunctiva, nasal, pharyngeal, laryngeal, esophageal, genital and anal 
mucosa as well. Blisters typically rupture more easily on the mucosa than on the skin [64].
Oral lesions present a challenge, give their slow response to treatment in comparison to 
cutaneous lesions. When patients have low titers of circulating antibodies, lesions can be 
Figure 8. Patient with pemphigus vulgaris in the oral mucosa.
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controlled temporarily with mouthwashes or topical creams that contain corticosteroids. 
These include 0.1% triamcinolone acetonide in orabase, 0.05% fluocinolone acetonide, 
0.05% clobetasol propionate, or 0.05% halobetasol. Intralesional injection of triamcinolone 
acetonide (20 μg/L) or paramethasone every 5–15 days can be used in refractory lesions. 
However, the treatment should be withdrawn if symptoms do not improve after three 
injections [64].
To improve the wellbeing of patients suffering from mucosal lesions, it is recommended 
to administer analgesics, maintain oral hygiene using diluted antiseptic (chlorohexidine) 
mouthwashes, periodontal treatment, following a soft diet without irritants, checking pros-
thetic restorations, and applying anti-candida therapy in patients on long-term corticosteroid 
treatments [64].
Since oral trauma can trigger or worsen pemphigus vulgaris, Bystrn et al. recommended the 
prophylactic administration of 20 mg prednisone/day in addition to the patient’s normal 
requirement for 5–7 days before any dental procedure that is associated with trauma to the 
gums [2].
The nostrils should be cleaned daily with a sterile cotton swab that is moistened with isotonic 
sterile sodium chloride solution. Antibiotic ointment should also be applied to the nostrils. 
The mouth should be rinsed a few times a day using a syringe with isotonic sterile sodium 
chloride solution [2].
18. Conclusion
There is current controversy on how to achieve optimal wound management of this dis-
ease. When the disease becomes severe, patients are typically admitted to the burn unit. 
Therefore, the supportive care resembles that performed for severe thermal burns TEN. It 
aims at minimizing potential complications which may ultimately lead to patient mortality. 
For instance, it aims to avoid hypovolemia, electrolyte imbalance, renal insufficiency and 
sepsis [24].
Careful wound care, hydration and nutritional support are critical and performed in an 
intensive care unit if there is epidermal detachment involving 10–20% or more of body 
surface area. Current wound care recommendations include using controlled pressure as 
well as thermoregulated bed and sheets. It is essential for all procedures to occur in a 
sterile environment and for venous catheters to only be placed in regions of non-involved 
skin [65].
It is advised that wound care be performed under the guidance of a dermatologist, due to the 
complex issues these patients face. Cutaneous care should include the face, eyes, nose, mouth, 
ear, anogenital region, axillary folds and interdigital spaces. When cutaneous areas are non-
detached, the must be kept dry and not manipulated. However, detached cutaneous areas 
should be covered with Vaseline gauze until reepithelization has occurred [24].
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